top of page

Acuitas Therapeutics is a pioneer in developing lipid nanoparticles, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine

  • Mar 12, 2025
  • 1 min read

Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page